We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · October 29, 2021

Long-Term Real-World Efficacy Outcomes of Natalizumab vs Fingolimod in RRMS

Frontiers in Neurology


Additional Info

Disclosure statements are available on the authors' profiles:

Frontiers in Neurology
Long-Term Efficacy Outcomes of Natalizumab vs. Fingolimod in Patients With Highly Active Relapsing-Remitting Multiple Sclerosis: Real-World Data From a Multiple Sclerosis Reference Center
Front Neurol 2021 Oct 01;12(xx)699844, M Boziki, C Bakirtzis, V Giantzi, SA Sintila, S Kallivoulos, T Afrantou, I Nikolaidis, P Ioannidis, T Karapanayiotides, I Koutroulou, D Parissis, N Grigoriadis

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading